All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10365940" target="_blank" >RIV/00216208:11150/17:10365940 - isvavai.cz</a>

  • Alternative codes found

    RIV/00179906:_____/17:10365940

  • Result on the web

    <a href="http://dx.doi.org/10.1007/s11239-017-1476-2" target="_blank" >http://dx.doi.org/10.1007/s11239-017-1476-2</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s11239-017-1476-2" target="_blank" >10.1007/s11239-017-1476-2</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases

  • Original language description

    Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile compared with vitamin K antagonists. However, the lack of specific reversal agents has made the management of some patients receiving long-term treatment with NOACs problematic in emergency situations such as major bleeding events or urgent procedures. Idarucizumab, a fully humanized Fab antibody fragment that binds specifically and with high affinity to dabigatran, was recently approved for use in adult patients treated with dabigatran when rapid reversal of its anticoagulant effect is required. Clinical experience with idarucizumab is currently limited. We report 11 real-life clinical cases in which idarucizumab was used after multidisciplinary consultation in a variety of emergency situations including severe postoperative bleeding, emergency high-bleeding-risk surgery (hip/spine surgery and neurosurgery), invasive diagnostic testing (lumbar puncture), intracranial bleeding (pre-pontine subarachnoid hemorrhage and lobar intracerebral hemorrhage) and thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke. This case series illustrates the role of idarucizumab in improving patient safety in rare emergency situations requiring rapid reversal of the anticoagulant effect of dabigatran, while highlighting the importance of information and education about the availability and appropriate use of this recently approved specific reversal agent.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Thrombosis and Thrombolysis

  • ISSN

    0929-5305

  • e-ISSN

  • Volume of the periodical

    43

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    12

  • Pages from-to

    306-317

  • UT code for WoS article

    000395829100004

  • EID of the result in the Scopus database

    2-s2.0-85013103925